Can I get it?
Yes, if a doctor decides it is right for you. Testosterone replacement is authorised in the EU and can be prescribed after a medical review.

APPROVED IN THE EUTestosterone replacement is authorised in the EU.
We don't prescribe it today, but our doctors can review your case and propose an equivalent sexual health treatment with EU approval and clinical evidence.
IN PLAIN TERMS
Testosterone replacement therapy, often shortened to TRT, is a hormone treatment given as a gel, patch or injection for men whose bodies genuinely do not make enough testosterone, a condition called hypogonadism. Testosterone medicines are authorised across EU countries, but only for that diagnosis: European regulators require low testosterone to be confirmed by both symptoms and blood tests before treatment starts, and they require haemoglobin, liver function and blood fats to be checked regularly while it continues. It is not authorised as a lifestyle, anti-ageing or performance treatment, and it is not an erectile dysfunction medicine. Hi-Doctor does not prescribe testosterone online on demand, because starting it needs repeat blood tests, a physical assessment and long-term follow-up that an online questionnaire cannot replace; if the problem you actually want help with is erections, that is a separate conversation with a doctor.
Testosterone replacement is an authorised medicine in the EU, so a licensed doctor can prescribe it when it is clinically appropriate for you.
Yes, if a doctor decides it is right for you. Testosterone replacement is authorised in the EU and can be prescribed after a medical review.
Our doctors review every Sexual health option and recommend what fits your history and goals.
See all Sexual health optionsEvery trial behind Testosterone replacement is listed below with its registry number, how many people took part, and whether the results are peer-reviewed or a company announcement.
Jump to the studiesLocal consultation facts
Not through Hi-Doctor. Hi-Doctor does not prescribe Testosterone replacement. People in Liepāja, Latvia, can request an online consultation for Sexual health with a licensed EU doctor, who may recommend an available option when clinically appropriate. If approved, the EU prescription arrives as a PDF for a pharmacist in Latvia, who dispenses the locally marketed equivalent with the prescribed active ingredient.
Availability
Hi-Doctor does not prescribe Testosterone replacement. The links below show options in Sexual health that our doctors can assess.
How the EU prescription works where you are: In Latvia, show the approved prescription PDF to a pharmacist. They honour it under EU cross-border rules and dispense the locally marketed equivalent with the prescribed active ingredient.
TREATMENT OPTIONS
A licensed doctor decides case by case. We never prescribe without evaluation.

Rx · PDE5 inhibitor
Phosphodiesterase-5 inhibitor. The doctor assesses it after ruling out cardiovascular contraindications.
Fast-acting tablets

Rx · PDE5 inhibitor
Long-acting PDE5 inhibitor. Available in low doses for daily use or higher doses on demand.
Tablets

Rx · PDE5 inhibitor
Alternative within the same class, sometimes better tolerated depending on the patient's profile.
Tablets

Rx · PDE5 inhibitor
Faster-acting PDE5 inhibitor. An option for selected patients based on medical judgement.
Tablets

Rx · topical cream
Topical option for patients who don't respond to PDE5 inhibitors or have contraindications. The doctor assesses suitability.
Topical cream
You pay for any medication separately at the pharmacy you choose. Hi-Doctor does not sell medications.
WHAT IT COSTS
ONE-OFF
€35 one-off
One consultation, one doctor, one decision.
Nothing stored publicly, ever
Full refund if a review is not approved
WHAT'S INCLUDED
Full refund if a review is not approved
If a review is not approved, we refund the €35 consultation fee in full.
Note: The medication, if the doctor prescribes it, is paid separately at the pharmacy at the price it sets. Hi-Doctor does not sell medications.
VERIFIED EVIDENCE
WHAT IT IS
Testosterone replacement tops up the body's own supply of the hormone when the testicles or the glands controlling them are not making enough, and the hormone then acts on androgen receptors in muscle, bone, brain and sexual tissue.
DEVELOPMENT STAGE
Every NCT identifier links to its ClinicalTrials.gov record. A readout is not the same as peer-reviewed publication.
| TRIAL / NCT | POPULATION | PARTICIPANTS | STATUS | READOUT / COMPLETION |
|---|---|---|---|---|
| TRAVERSE (cardiovascular safety of testosterone-replacement therapy)NCT03518034 | Men aged 45 to 80 with symptoms of hypogonadism, two fasting testosterone levels below 300 ng/dL, and existing or high cardiovascular risk | 5,246 | Read out | 2023-07-13 |
| The Testosterone Trials (including the Sexual Function Trial, n=470)NCT00799617 | Men aged 65 and over with average testosterone below 275 ng/dL and symptoms suggesting low testosterone, at twelve US academic medical centres | 790 | Read out | 2016-02-18 |
Results are grouped by source and evidence grade so journal data and manufacturer announcements cannot be confused.
| DOSE OR GROUP | MEAN WEIGHT CHANGE | WEEKS |
|---|---|---|
| Testosterone gel for 1 year, men aged 65+ with testosterone below 275 ng/dL | Significantly increased sexual activity on the Psychosexual Daily Questionnaire (P<0.001), with significantly increased sexual desire and erectile function | 52 |
| Testosterone gel for 1 year, Sexual Function Trial (n=470) | 10 of 12 measures of sexual activity improved compared with placebo; no threshold testosterone level was identified for any outcome | 52 |
These results come only from men aged 65 and over whose low testosterone was confirmed by blood tests; they say nothing about men with normal testosterone levels, and the trial authors state the study was too small to draw conclusions about the risks of treatment.
Last reviewed 2026-07-27
NAMED SAFETY SIGNALS
In TRAVERSE a first cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 182 men on testosterone (7.0%) and 190 on placebo (7.3%); hazard ratio 0.96, 95% CI 0.78 to 1.17, meeting the trial's non-inferiority criterion.
TRAVERSE reported a higher incidence of atrial fibrillation, acute kidney injury and pulmonary embolism in the testosterone group than in the placebo group.
After an EU-wide review that opened on 10 April 2014 and closed with the CMDh position of 8 January 2015, product information was changed to state that testosterone should only be used when an abnormally low hormone level has been confirmed by signs and symptoms and by appropriate laboratory tests. The EMA states that restoring levels in healthy older men is not an authorised use.
The same EU review requires prescribers to monitor haemoglobin, liver function and blood lipids regularly during treatment, and added warnings for patients at increased cardiovascular risk.
FREQUENTLY ASKED QUESTIONS
OTHER SEXUAL HEALTH TREATMENTS
HI-DOCTOR NEWSLETTER
At most 2 emails a month. No spam. Updates on online health, EU telemedicine, and clinical guides signed by licensed doctors.